## BioTox




Current safety testing relies on animal models, which are costly, time-consuming, and often ineffective in predicting human responses.

🔀 Biolligence


BioTox is at the forefront of a transformative shift in drug testing by leveraging cutting-edge technologies. Our platform integrates advanced Al-driven, physics based multi-modal algorithms with human-relevant data sources, such as cell-based assays, clinical information and high-throughput screening methods. BioTox delivers highly precise toxicity predictions faster and more cost-effectively, reducing the dependence on animal models.

With the recent FDA Modernization Act 2.0 and European Parliament resolutions supporting non-animal testing methods, BioTox is positioned at the forefront of this regulatory and scientific shift.

Our platform offers a scalable, ethical, and cost-effective alternative to traditional safety assessments, leveraging human-centric data and advanced AI to provide precise toxicity predictions at population scale. By reducing reliance on animal testing for drug toxicity prediction, we accelerate drug discovery with faster, more accurate insights, supporting safer and more efficient clinical trials for precision medicine.




## Industry Challenges



## Platform

BioTox replaces traditional animal testing with Al-driven *in-vitro* models, offering precise, human-relevant data faster and at lower costs.

Our platform predicts neurotoxicity, cardiotoxicity, and other safety concerns across the drug development lifecycle.



Biolligence revolutionizes drug discovery by integrating deep learning and stem cells to deliver safer, more accurate preclinical testing

enabling precision clinical trials.

## Our offices: Oxford, United Kingdom | Pune, India

Visit: <u>www.biolligence.com</u>; For more information please reach out – hello@biolligence.com